Human anti-EBOV GP mAb (KZ52)

Product Description

Human anti-EBOV GP mAb (KZ52) is available at Gentaur for Next Week Delivery.

Product Type: monoclonal antibody

Host: Human

Applications: ELISA

Immunogen:The human antibody KZ52 was derived from a human convalescent patient who survived an Ebola virus (EBOV) infection. KZ52 is directed towards
the EBOV glycoprotein (GP).

Description: Protein A purified neutralizing human monoclonal antibody reactive to EBOV GP (Parren et al). The antibody detects recombinant EBOV GP without the
transmembrane region (EBOV rGPΔTM) expressed in both mammalian and insect cells.

Supplied: 100 µg is supplied in buffer containing Histidine, sodium chloride and sucrose at a concentration of 1.732 mg/mL. No preservative is added.

Purification: Antibody is purified using immobilized protein A.

Clonality: Human variable, human constant of the IgG1 isotype.

Relevance: The antibody can be used for detection of EBOV GP.

References: Lee et al. Nature, 454:177-182 (2008)
Parren et al. J. Virol., 76:6408-6412 (2002)

Recommended Dilutions:
ELISA: Assay-dependent dilution. Internal QC demonstrates good detection of recombinant EBOV GP coated to a microtiter plate at 1 µg/mL when using KZ52 mAb at a concentration between 10 – 0.001 µg/mL. Neutralization Assay: KZ52 lot 1605006 showed similar neutralization activity compared to KZ52 reference lot 1603003.

WB: Not suitable for Western Blot analysis.

Storage: 2-3 weeks +4°C, -20°C long term

Cross Reactivity: No cross-reactivity was observed to Sudan Virus (SUDV) or Marburg Virus (MARV) GP or virus-like particles (VLPs)

ELISA Data:

Recombinant GP proteins were diluted to 1 µg/mL and
virus-like particles (VLPs) expressing GP proteins were
diluted to 10 µg/mL in PBS for plate coating. Anti-EBOV
GP antibody (KZ52) was serially diluted semi-log from
10 µg/mL and incubated on the coated plates. Washed
plates were detected with anti-human IgG-HRP
conjugate and TMB substrate. OD650 is reported above.

Neutralization Assay:

Antibody was incubated with vesicular stomatitis
viruses (VSV) pseudotyped with Ebola GP and
expressing Luciferase (EBOV-VSV) for one hour prior to
infectivity on Vero cell monolayers. Infectivity was
determined 24 hou